AI Article Synopsis
- - A case was reported involving a 39-year-old man who developed idiopathic refractory ascites after undergoing allogeneic hematopoietic cell transplantation.
- - The patient's ascites were linked to high portal venous pressure but showed no signs of common complications, leading to the administration of ibrutinib as treatment.
- - Following treatment with ibrutinib, the patient's ascites improved significantly, contributing to a better understanding of the condition's mechanisms and potential treatment strategies.
Article Abstract
We herein report a case of idiopathic refractory ascites following allogeneic hematopoietic cell transplantation that was successfully treated with ibrutinib. A 39-year-old man presented with massive transudative ascites. Despite a high portal venous pressure, the liver histology showed traces of alloreactivity inconsistent with veno-occlusive disease/sinusoidal obstructive syndrome. Ibrutinib was administered for ascites possibly secondary to portal hypertension associated with the alloreactivity. The ascites dramatically improved, and the portal venous pressure was reduced. This case may help clarify the mechanism through which refractory ascites develops after allogeneic hematopoietic cell transplantation and establish appropriate treatment protocols.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569935 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.1139-22 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!